Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients.
Correale P, Botta C, Martino EC, Ulivieri C, Battaglia G, Carfagno T, Rossetti MG, Fioravanti A, Guidelli GM, Cheleschi S, Gandolfo C, Carbone F, Baldari TC, Tassone P, Tagliaferri P, Pirtoli L, Cusi MG. Correale P, et al. Among authors: pirtoli l. Oncoimmunology. 2015 Dec 21;5(4):e1101205. doi: 10.1080/2162402X.2015.1101205. eCollection 2016 Apr. Oncoimmunology. 2015. PMID: 27141384 Free PMC article.
Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients.
Cusi MG, Botta C, Pastina P, Rossetti MG, Dreassi E, Guidelli GM, Fioravanti A, Martino EC, Gandolfo C, Pagliuchi M, Basile A, Carbone SF, Ricci V, Micheli L, Tassone P, Tagliaferri P, Pirtoli L, Correale P. Cusi MG, et al. Among authors: pirtoli l. Cancer Immunol Immunother. 2015 Sep;64(9):1159-73. doi: 10.1007/s00262-015-1711-7. Epub 2015 Jun 2. Cancer Immunol Immunother. 2015. PMID: 26031574 Free PMC article. Clinical Trial.
Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine.
Correale P, Botta C, Staropoli N, Nardone V, Pastina P, Ulivieri C, Gandolfo C, Baldari TC, Lazzi S, Ciliberto D, Giannicola R, Fioravanti A, Giordano A, Zappavigna S, Caraglia M, Tassone P, Pirtoli L, Cusi MG, Tagliaferri P. Correale P, et al. Among authors: pirtoli l. Oncotarget. 2018 Apr 17;9(29):20539-20554. doi: 10.18632/oncotarget.24993. eCollection 2018 Apr 17. Oncotarget. 2018. PMID: 29755670 Free PMC article.
Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients.
Martino EC, Misso G, Pastina P, Costantini S, Vanni F, Gandolfo C, Botta C, Capone F, Lombardi A, Pirtoli L, Tassone P, Ulivieri C, Tagliaferri P, Cusi MG, Caraglia M, Correale P. Martino EC, et al. Among authors: pirtoli l. Cell Death Discov. 2016 Oct 3;2:16025. doi: 10.1038/cddiscovery.2016.25. eCollection 2016. Cell Death Discov. 2016. PMID: 27752361 Free PMC article.
Immunotherapy of colorectal cancer: new perspectives after a long path.
Correale P, Botta C, Ciliberto D, Pastina P, Ingargiola R, Zappavigna S, Tassone P, Pirtoli L, Caraglia M, Tagliaferri P. Correale P, et al. Among authors: pirtoli l. Immunotherapy. 2016 Nov;8(11):1281-1292. doi: 10.2217/imt-2016-0089. Immunotherapy. 2016. PMID: 27993089 Review.
Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients.
Pastina P, Nardone V, Croci S, Battaglia G, Vanni F, Bellan C, Barbarino M, Ricci V, Costantini S, Capone F, Botta C, Zarone MR, Misso G, Boccellino M, Caraglia M, Giordano A, Paladini P, Tassone P, Tagliaferri P, Cusi MG, Pirtoli L, Correale P. Pastina P, et al. Among authors: pirtoli l. J Thorac Dis. 2017 Sep;9(9):3123-3131. doi: 10.21037/jtd.2017.08.68. J Thorac Dis. 2017. PMID: 29221287 Free PMC article.
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up.
Caraglia M, Correale P, Giannicola R, Staropoli N, Botta C, Pastina P, Nesci A, Caporlingua N, Francini E, Ridolfi L, Mini E, Roviello G, Ciliberto D, Agostino RM, Strangio A, Azzarello D, Nardone V, Falzea A, Cappabianca S, Bocchetti M, D'Arrigo G, Tripepi G, Tassone P, Addeo R, Giordano A, Pirtoli L, Francini G, Tagliaferri P. Caraglia M, et al. Among authors: pirtoli l. Front Oncol. 2019 Nov 8;9:1102. doi: 10.3389/fonc.2019.01102. eCollection 2019. Front Oncol. 2019. PMID: 31781481 Free PMC article.
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial.
Correale P, Botta C, Rotundo MS, Guglielmo A, Conca R, Licchetta A, Pastina P, Bestoso E, Ciliberto D, Cusi MG, Fioravanti A, Guidelli GM, Bianco MT, Misso G, Martino E, Caraglia M, Tassone P, Mini E, Mantovani G, Ridolfi R, Pirtoli L, Tagliaferri P. Correale P, et al. Among authors: pirtoli l. J Immunother. 2014 Jan;37(1):26-35. doi: 10.1097/CJI.0000000000000004. J Immunother. 2014. PMID: 24316553 Clinical Trial.
Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev).
Pastina P, Nardone V, Botta C, Croci S, Tini P, Battaglia G, Ricci V, Cusi MG, Gandolfo C, Misso G, Zappavigna S, Caraglia M, Giordano A, Aldinucci D, Tassone P, Tagliaferri P, Pirtoli L, Correale P. Pastina P, et al. Among authors: pirtoli l. Oncotarget. 2017 Aug 24;8(44):75904-75913. doi: 10.18632/oncotarget.20411. eCollection 2017 Sep 29. Oncotarget. 2017. PMID: 29100279 Free PMC article.
132 results